Methods of treating mental and/or mood disorders using 2-bromo-lsd alone or in combination with a mtor inhibitor
AssigneeBetterlife Pharma Inc.
InventorJustin KIRKLAND
Life of this patent
Estimating the term…
Abstract
Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceutical compositions that comprise 2-bromo-LSD and/or a mTOR inhibitor as well as dosage formulations and dosage regimes thereof.
Claims85
A method of treating major depressive disorder comprising administering to a subject a therapeutically effective amount of 2-Bromo-LSD or a derivative or salt thereof.
A method of treating a mental disorder and/or a mood disorder comprising administering to a subject a therapeutically effective amount of 2-Bromo-LSD or a derivative or salt thereof,
- wherein the mental disorder and/or the mood disorder is selected from the group consisting of Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Atypical Depression, Melancholid Depression, Psychotic major depression, Catatonic Depression, Postpartum Depression, Premenstrual dysphoric disorder, Seasonal affective disorder, Dysthymia Double Depression, Depressive Disorder Not Otherwise Specified, Depressive personality disorder, Recurrent brief depression, and Minor Depressive disorder.
A method of treating a bipolar disorder comprising administering to a subject a therapeutically effective amount of 2-Bromo-LSD or a derivative or salt thereof.
A method of treating a mental disorder and/or a mood disorder comprising administering to a subject a therapeutically effective amount of 2-Bromo-LSD or a derivative or salt thereof, wherein the mental disorder and/or the mood disorder is selected from the group consisting of impulse-control disorders, adjustment disorders, and personality disorders.
A method of treating major depressive disorder in a subject in need thereof, wherein the subject has been diagnosed with the major depressive disorder, comprising:
- administering a therapeutically effective amount of a mTOR inhibitor and a therapeutically effective amount of 2-Bromo-LSD to the subject,
- wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof.
A method of lessening or alleviating severity of a major depressive disorder in a subject in need thereof, wherein the subject has been diagnosed with the major depressive disorder, comprising:
- administering a therapeutically effective amount of a mTOR inhibitor to the subject;
- and
- administering a therapeutically effective amount of 2-Bromo-LSD to the subject,
- wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof.
A method of treating a mental disorder or a mood disorder comprising co-administering to a subject in need of treatment thereof (i) a therapeutically effective amount of a pharmaceutical composition comprising 2-Bromo-LSD;
- and (ii) a therapeutically effective amount of a pharmaceutical composition comprising a mTOR inhibitor.
- wherein the mental disorder and/or the mood disorder is selected from the group consisting of Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Atypical Depression, Melancholid Depression, Psychotic major depression, Catatonic Depression, Postpartum Depression, Premenstrual dysphoric disorder, Seasonal affective disorder, Dysthymia Double Depression, Depressive Disorder Not Otherwise Specified, Depressive personality disorder, Recurrent brief depression, and Minor Depressive disorder.
A method of prolonging an antidepressant effect of 2-Bromo-LSD, comprising:
- administering a therapeutically effective amount of a mTOR inhibitor to a subject;
- and
- administering a therapeutically effective amount of 2-Bromo-LSD to the subject,
- wherein the antidepressant effect of the 2-Bromo-LSD is extended
A composition comprising:
- (i) a therapeutically effective dose of an mTOR inhibitor;
- (ii) a therapeutically effective dose of 2-Bromo-LSD;
- and (iii) a pharmaceutically acceptable carrier or excipient.
A kit comprising:
- (i) a therapeutically effective dose of an mTOR inhibitor;
- and (ii) a therapeutically effective dose of 2-Bromo-LSD, and optional instructions for use.
A capsule comprising about 2.0 mg to about 3.5 mg 2-bromo-LSD, about 296.5 to about 298 mg microcrystalline cellulose, and about 3 mg silicon dioxide or magnesium stearate.
A tablet comprising about 2.0 mg to about 3.5 mg 2-bromo-LSD, about 296.5 to about 298 mg microcrystalline cellulose, and about 3 mg silicon dioxide or magnesium stearate.
A oral dissolving tablet comprising about 2.0 mg to about 3.5 mg 2-bromo-LSD, about 1.0 mg to about 162.5 mg microcrystalline cellulose, about 1.0 mg to about 162.5 mg D-mannitol, about 1.0 mg to about 162.5 mg xylitol, about 1.0 mg to about 162.5 mg crospovidone, about 1.0 mg to about 162.5 mg dibasic calcium phosphate anhydrous and about 1.25 mg magnesium stearate,
- wherein said oral dissolving tablet has a compression range of about 34 to about 40 Newtons (N), and
- wherein said oral dissolving tablet has a disintegration time of fewer than about 30 seconds.
A composition for use in the treatment of a mental or mood disorder, the composition comprising:
- a therapeutically effective dose of an mTOR inhibitor, and
- a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.